Firefly Newborn Phototherapy

CONDITION ADDRESSED: Jaundice

Treatment
Treatment
  • PREVENTION
  • DIAGNOSTIC
  • TREATMENT
Firefly Newborn Phototherapy

CONTACT INFORMATION

Organization

Design that Matters

Individual Contact

Timothy Prestero | Email

Applications

10% of all newborns worldwide require jaundice treatment to prevent death or lifelong disability. Phototherapy, shining a blue light on the skin, is the most cost-effective way to treat jaundice, however every year 5.7 million infants in South Asia and Africa do not receive any phototherapy. Global health experts estimate 6-10% of newborn mortality can be attributed to jaundice and complications caused by jaundice.

Advantages

Firefly phototherapy is the first device that Vietnamese clinicians trust to use in the room with mothers in rural hospitals--a context that supports an optimal cycle of newborn phototherapy and feeding for rapid and effective treatment. The combination top and bottom phototherapy, robust enclosed housings, table-top size, removable and cleanable single-infant bassinet, and high-tech medical aesthetic make it the most trustworthy, intuitive and effective phototherapy device affordable for low-resource, remote settings in Vietnam and Southeast Asia.

Milestones

During the 2011 Firefly clinical evaluation at National OBGYN Hanoi, DtM verified that we have created the world’s most effective phototherapy device for hospitals in the developing world. The clinical test results revealed treatment duration times cut significantly, and the ability to cure even the most severe jaundice cases. The tests included two infants with cases so severe, the doctors were certain they would have to resort to costly and dangerous blood transfusions, but instead Firefly averted this fate.

Partners

  • East Meets West Foundation
  • Medical Technology Transfer and Services

+ More than 300 collaborators in the U.S. and internationally

Proposed next steps in development

Complete installation of production line

Stage of Development

Field/clinical studies

Funding Source

The Lemelson Foundation; The van Otterloo Family; Bohemian Foundation; An Anonymous Donor; ANT Italy